バイオリソース室

Naoki Yamamoto

  (山本 直樹)

Profile Information

Affiliation
Professor, Center for Society-Academia Collaboration, Research Promotion Headquarters, Fujita Health University
(Concurrent)Professor, International Center for Cell and Gene Therapy, Research Promotion Headquarters
(Concurrent)Professor, Graduate School of Medical Sciences
Degree
医学博士(藤田保健衛生大学)

Contact information
naokiyfujita-hu.ac.jp
Researcher number
00267957
J-GLOBAL ID
200901054071171303
researchmap Member ID
6000005815

External link

Education

 1

Papers

 199
  • Yosuke Nakazawa, Yumika Kuno, Hibiki Shimada, Noriaki Nagai, Noriko Hiramatsu, Shun Takeda, Naoki Yamamoto, Megumi Funakoshi-Tago, Hiroshi Sasaki
    Medical molecular morphology, Jul 9, 2024  
    The prevalence of presbyopia and nuclear cataracts (NUC) is reported to be higher in tropical areas than that in other regions, suggesting a potential influence of high temperatures on lens health. Transient receptor potential vanilloid (TRPV) channels play a crucial role in detecting ambient temperatures across various species, with TRPV1 and TRPV4 expressed in lens epithelial cells. In this study, we investigated whether ambient temperatures affect TRPV1 and TRPV4 activity in the lens, potentially contributing to the development of presbyopia and NUC. We conducted experiments using cultured human lens epithelial cell lines under different temperature conditions. Our results revealed that the mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) and p38 pathways, downstream molecules of TRPV1, were activated, while Src family kinase, a downstream molecule of TRPV4, was inhibited at 37.5 °C culture compared to 35.0 °C. Confocal microscope images demonstrated higher expression of TRPV1 in 3D-structured cells under high-temperature culture conditions. Additionally, in organ culture lenses, higher elasticity was observed at elevated temperatures compared to that at lower temperatures. These results suggest that high ambient temperatures may induce lens sclerosis via TRPV1 activation, potentially contributing to the development of presbyopia and NUC.
  • Naoki YAMAMOTO, Noriko Hiramatsu, Yoshinao Kato, Atsushi Sato, Hajime Kojima
    Bioengineering, Mar, 2024  
  • Takuya Okamura, Sayako Morikawa, Tomoya Horiguchi, Kumiko Yamatsuta, Toshikazu Watanabe, Aki Ikeda, Yuri Maeda, Takuma Ina, Hideaki Takahashi, Ryoma Moriya, Yasuhiro Goto, Sumito Isogai, Naoki Yamamoto, Shotaro Okachi, Naozumi Hashimoto, Kazuyoshi Imaizumi
    Respiration; international review of thoracic diseases, 103(4) 171-176, Feb 22, 2024  
    INTRODUCTION: Increasing numbers of cases of mild asymptomatic pulmonary alveolar proteinosis (PAP) are being reported with the recent increase in chest computed tomography (CT). Bronchoscopic diagnosis of mild PAP is challenging because of the patchy distribution of lesions, which makes it difficult to obtain sufficient biopsy samples. Additionally, the pathological findings of mild PAP, particularly those that differ from severe PAP, have not been fully elucidated. This study aimed to clarify the pathological findings of mild PAP and the usefulness of optical biopsy using probe-based confocal laser endomicroscopy (pCLE). METHODS: We performed bronchoscopic optical biopsy using pCLE and tissue biopsy in five consecutive patients with PAP (three with mild PAP and two with severe PAP). We compared the pCLE images of mild PAP with those of severe PAP by integrating clinical findings, tissue pathology, and chest computed tomography images. RESULTS: pCLE images of PAP showed giant cells with strong fluorescence, amorphous substances, and thin alveolar walls. Images of affected lesions in mild PAP were equivalent to those obtained in arbitrary lung lesions in severe cases. All three patients with mild PAP spontaneously improved or remained stable after ≥3 years of follow-up. Serum autoantibodies to granulocyte-macrophage colony-stimulating factor were detected in all five cases. CONCLUSION: Optical biopsy using pCLE can yield specific diagnostic findings, even in patients with mild PAP. pCLE images of affected areas in mild and severe PAP showed similar findings, indicating that the dysfunction level of pathogenic alveolar macrophages in affected areas is similar between both disease intensities.
  • Takahiro Inoue, Sumito Isogai, Naoki Yamamoto, Noriko Hiramatsu, Yoshikazu Niwa, Hideaki Takahashi, Yutaro Kimura, Tomoya Horiguchi, Yasuhiro Goto, Naozumi Hashimoto, Kazuyoshi Imaizumi
    Therapeutic advances in respiratory disease, 18 17534666241254980-17534666241254980, 2024  
    BACKGROUND: Bronchial thermoplasty (BT) is a recently developed non-pharmacological therapy for refractory bronchial asthma. Although increasing evidence has suggested that BT is effective for various phenotypes of severe asthma, its safety and efficacy in patients with severe irreversible impaired lung function are unclear. OBJECTIVES: To assess the efficacy and safety of BT in patients with refractory asthma, including patients with a severely impaired forced expiratory volume in 1 second (FEV1). DESIGN: This was a single-center, retrospective, observational cohort study. METHODS: We retrospectively reviewed the medical records of 15 patients with refractory asthma (Global Initiative for Asthma step 4 or 5), including patients with severely impaired airflow limitation (% predicted pre-bronchodilator FEV1 <60%), who had undergone BT between June 2016 and January 2022. We analyzed the efficacy (change in asthma symptoms, exacerbation rate, pulmonary function, asthma medication, and serum inflammatory chemokine/cytokines before and after BT) and complications in all patients. We compared these data between patients with severe obstructive lung dysfunction [group 1(G1)] and patients with FEV1 ⩾ 60% [group 2 (G2)]. RESULTS: Six patients were in G1 and nine were in G2. Clinical characteristics, T2 inflammation, and concurrent treatment were equivalent in both groups. BT significantly improved asthma-related symptoms (measured using the Asthma Control Test and Asthma Quality of Life Questionnaire scores) in both groups. FEV1 was significantly improved in G1 but not in G2. Four patients in G2, but none in G1, experienced asthma exacerbation requiring additional systemic corticosteroids (including two requiring prolonged hospitalization) after BT. Long-term responders (patients who reduced systemic or inhaled corticosteroid without newly adding biologics in a follow-up > 2 years) of BT were identified in G1 and G2 (n = 2, 33.3% and n = 4, 44.4%, respectively). CONCLUSION: BT in patients with refractory asthma and severe airflow limitation is equally safe and efficacious as that in patients with moderate airflow limitation.
  • Yuri Doki, Yosuke Nakazawa, Miyu Sukegawa, Rosica S Petrova, Yuki Ishida, Shin Endo, Noriaki Nagai, Naoki Yamamoto, Megumi Funakoshi-Tago, Paul J Donaldson
    Experimental eye research, 237 109719-109719, Dec, 2023  
    Presbyopia is caused by age-related lenticular hardening, resulting in near vision loss, and it occurs in almost every individual aged ≥50 years. The lens experiences mechanical pressure during for focal adjustment to change its thickness. As lenticular stiffening results in incomplete thickness changes, near vision is reduced, which is known as presbyopia. Piezo1 is a mechanosensitive channel that constantly senses pressure changes during the regulation of visual acuity, and changes in Piezo1 channel activity may contribute to presbyopia. However, no studies have reported on Piezo1 activation or the onset of presbyopia. To elucidate the relevance of Piezo1 activation and cross-linking in the development of presbyopia, we analysed the function of Piezo1 in the lens. The addition of Yoda1, a Piezo1 activator, induced an increase in transglutaminase 2 (TGM2) mRNA expression and activity through the extra-cellular signal-regulated kinase (ERK) 1/2 and c-Jun-NH2-terminal kinase1/2 pathways. In ex vivo lenses, Yoda1 treatment induced γ-crystallin cross-linking via TMG2 activation. Furthermore, Yoda1 eye-drops in mice led to lenticular hardening via TGM2 induction and activation in vivo, suggesting that Yoda1-treated animals could serve as a model for presbyopia. Our findings indicate that this presbyopia-animal model could be useful for screening drugs for lens-stiffening inhibition.

Misc.

 56
  • 門脇玲太, 浅井拓己, 出口粧央里, 大竹裕子, 中澤洋介, 山本直樹, 長井紀章
    日本白内障学会総会・水晶体研究会プログラム・講演抄録集, 62nd-49th, 2023  
  • 山本直樹, 山本直樹, 平松範子, 佐々木洋, 近藤征史, 小島肇
    Journal of Toxicological Sciences, 46(Supplement), 2021  
  • 林 卓馬, 山本 直樹, 田島 香里, 長谷川 正樹, 谷口 巧, 藤田 順之, 石村 大輔
    日本整形外科学会雑誌, 94(8) S1859-S1859, Sep, 2020  
  • Tomohide Souma, Tomoyuki Minezawa, Hiroshi Yatsuya, Takuya Okamura, Kumiko Yamatsuta, Sayako Morikawa, Tomoya Horiguchi, Shingo Maeda, Yasuhiro Goto, Masamichi Hayashi, Sumito Isogai, Naoki Yamamoto, Masashi Kondo, Kazuyoshi Imaizumi
    Chest, 158(2) 797-807, Mar 4, 2020  
    BACKGROUND: Infectious complications after endobronchial ultrasound-guided transbronchial biopsy with a guide sheath (EBUS-GS-TBB) are serious in that they may delay or change scheduled subsequent therapy. The aim of this study was to identify risk factors for infection after EBUS-GS-TBB. RESEARCH QUESTION: What are the risk factors for infection after EBUS-GS-TBB? STUDY DESIGN AND METHODS: We retrospectively reviewed the medical records of 1,045 consecutive patients who had undergone EBUS-GS-TBB for peripheral lung lesions between January 2013 and December 2017 at Fujita Health University Hospital. We evaluated the following risk factors for infectious complications after EBUS-GS-TBB: relevant patient characteristics (age and comorbidities), lesion size, CT scan features of target lesion (intratumoral low-density areas [LDAs] and cavitation), stenosis of responsible bronchus observed by bronchoscopy, and laboratory data before EBUS-GS-TBB (WBC count and C-reactive protein concentration). RESULTS: Forty-seven of the study patients developed infectious complications (24 with pneumonia, 14 with intratumoral infection, three with lung abscess, three with pleuritis, and three with empyema), among whom the complication caused a delay in cancer treatment in 13 patients, cancellation of cancer treatment in seven patients, and death in three patients. Multivariate analysis showed that cavitation (P = .007), intratumoral LDAs (P < .001), and stenosis of responsible bronchus observed by bronchoscopy (P < .001) were significantly associated with infectious complications after EBUS-GS-TBB. Prophylactic antibiotics had been administered to 13 patients in the infection group. Propensity matched analysis could not show significant benefit of prophylactic antibiotics in preventing post-EBUS-GS-TBB infections. INTERPRETATION: Cavitation, LDAs for CT scan features of target lesions, and stenosis of responsible bronchus observed by bronchoscopy are risk factors of post-EBUS-GS-TBB infection. In the cohort, prophylactic antibiotics failed to prevent infectious complications.
  • 山本直樹, 平松範子, 久保江理, 佐々木洋
    日本白内障学会誌, 32(1), 2020  

Books and Other Publications

 10
  • 山本 直樹 (Role: Contributor, 第2章 動物実験代替法における評価モデル 、第3節 不死化ヒト角膜上皮細胞株を用いた眼刺激性試験代替法)
    株式会社 技術情報協会, Jun, 2018
  • 山本 直樹 (Role: Joint author, 細胞培養基盤技術)
    株式会社 じほう, Jun, 2013
  • 山本 直樹 (Role: Contributor, フルオレセイン漏出試験法(Fluorescein leakage test method; FL試験法))
    株式会社 シーエムシー出版, Jun, 2013
  • 山本 直樹 (Role: Contributor, アトピー白内障 -その発症に関与する要因とメカニズム-)
    学際企画株式会社, Jun, 2011
  • 山本 直樹 (Role: Contributor, 子どもに多い目の病気 “感染予防の必要性の有無と指導の実際")
    健学社, Oct, 2008

Presentations

 51

Teaching Experience

 7

Works

 1

Research Projects

 19

Industrial Property Rights

 4

Other

 3
  • 市販のリプログラミングベクターを用いて、ヒト末梢血単球由来iPS細胞を作製することに成功した。研究成果は、以下のジャーナルで報告している。Isogai S, Yamamoto N et al., Cell Reprogram 20(6), 347-355, 2018. Hiramatsu N, Yamamoto N et al., Med Mol Morphol 53(2), 63-72, 2020. *本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター(fuji-san@fujita-hu.ac.jp)まで
  • ヒト虹彩由来iPS細胞の作製に成功した。研究成果は、以下のジャーナルで報告している。Yamamoto N et al., Cells 10(4), 743, 2021. *本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター(fuji-san@fujita-hu.ac.jp)まで
  • 臓器・組織を迅速に固定できる固定液を発明。日本で特許を取得(特許3723204 難浸透性組織迅速固定液)。本特許の技術の一部を利用した商品(組織用迅速固定液 スーパーフィックス KY-500, クラボウ)が販売されている。他にも、本特許技術を用いた無ホルマリン固定液を開発中。 *本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター(fuji-san@fujita-hu.ac.jp)まで